林奇综合征的风险管理  

Lynch syndrome risk management

作　　者：沈燕如[1] 冶生芳 索朗央金[3] 陈晓红[3] 

机构地区：[1]西藏自治区人民医院,西藏自治区高原病研究所,西藏自治区拉萨市850000 [2]西藏自治区人民医院检验科,西藏自治区拉萨市850000 [3]西藏自治区人民医院消化内科,西藏自治区拉萨市850000

出　　处：《世界华人消化杂志》2016年第14期2191-2197,共7页World Chinese Journal of Digestology

摘　　要：林奇综合征曾被称为遗传性非息肉病性结直肠癌,是一种显性遗传性癌症综合征,由细胞错配修复基因的可遗传突变引起,易导致消化系统及女性生殖系统等肿瘤.目前林奇综合征的误诊漏诊率极高,本文就林奇综合征监测、手术、药物、生活方式、筛查等风险管理的最新进展做一综述.Lynch syndrome has been known as hereditary non-polyposis colorectal cancer（HNPCC）, and it is a dominantly inherited cancer syndrome caused by genetic mutations in cell mismatch repair genes, often leading to digestive system and female reproductive system tumors. At present, there is a high misdiagnosis rate for Lynch syndrome. This paper reviews the latest progress in Lynch syndrome risk management with regards to its monitoring, surgical treatment,pharmaceutical treatment, life style improvement and screening.

关 键 词：林奇综合征 错配修复基因 肿瘤 风险管理 

分 类 号：R73[医药卫生—肿瘤]